Published on

An urgent care operator in Ohio is one of the 14 sites in a phase 3 clinical trial for a prospective Allergan product to treat patients with diabetic gastroparesis (DG), a condition that slows or stops the movement of food from the stomach to the small intestine. The trial, officially titled A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis, is expected to run until April 5, 2022. Its participation in the trial is nothing new for Hometown Urgent Care and Research; on their website they thank the “patient volunteers which have allowed us to successfully complete over 125 clinical trials.” It goes on to detail areas in which its providers are able to provide treatment (gastroenterology, respiratory, pain management, family medicine, infectious disease and acute conditions) and notes that its urgent care database includes >374,000 patients.

Ohio Urgent Care Operators Takes Part in Phase 3 Trial for Diabetes-Related Treatment
Tagged on: